These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects. Tavori H; Rashid S; Fazio S Atherosclerosis; 2015 Feb; 238(2):264-70. PubMed ID: 25544176 [TBL] [Abstract][Full Text] [Related]
32. Lipid Management in Diabetes with a Focus on Emerging Therapies. Hoe E; Hegele RA Can J Diabetes; 2015 Dec; 39 Suppl 5():S183-90. PubMed ID: 26653256 [TBL] [Abstract][Full Text] [Related]
33. Other therapies for reducing low-density lipoprotein cholesterol: medications in development. Stein EA Endocrinol Metab Clin North Am; 2009 Mar; 38(1):99-119. PubMed ID: 19217514 [TBL] [Abstract][Full Text] [Related]
34. Alirocumab (Praluent) to lower LDL-Cholesterol. Med Lett Drugs Ther; 2015 Aug; 57(1475):113-5. PubMed ID: 26262881 [No Abstract] [Full Text] [Related]
35. PCSK9 Inhibition: Discovery, Current Evidence, and Potential Effects on LDL-C and Lp(a). Ferdinand KC; Nasser SA Cardiovasc Drugs Ther; 2015 Jun; 29(3):295-308. PubMed ID: 26068408 [TBL] [Abstract][Full Text] [Related]
36. [Risk of cardiovascular complications cut in half?]. Einecke D MMW Fortschr Med; 2015 Apr; 157(6):26. PubMed ID: 26015190 [No Abstract] [Full Text] [Related]
37. Novel therapeutic agents for lowering low density lipoprotein cholesterol. Joy TR Pharmacol Ther; 2012 Jul; 135(1):31-43. PubMed ID: 22465160 [TBL] [Abstract][Full Text] [Related]
38. Low-density lipoprotein cholesterol lowering therapies: what is on the horizon? Gadi R; Figueredo VM J Cardiovasc Med (Hagerstown); 2015 Jan; 16(1):1-10. PubMed ID: 25379719 [TBL] [Abstract][Full Text] [Related]
39. Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice. Denis M; Marcinkiewicz J; Zaid A; Gauthier D; Poirier S; Lazure C; Seidah NG; Prat A Circulation; 2012 Feb; 125(7):894-901. PubMed ID: 22261195 [TBL] [Abstract][Full Text] [Related]
40. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. Reiner Z Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]